Potentiation of Ibudilast Inhibition of Platelet Aggregation in the Presence of Endothelial Cells

  • Ge Rile
    Affiliations
    Department of Clinical and Laboratory Medicine, Yamanashi Medical University, Tamaho, Nakakoma, Yamanashi 409-3898, Japan
    Search for articles by this author
  • Yutaka Yatomi
    Affiliations
    Department of Clinical and Laboratory Medicine, Yamanashi Medical University, Tamaho, Nakakoma, Yamanashi 409-3898, Japan
    Search for articles by this author
  • Ruomei Qi
    Affiliations
    Department of Clinical and Laboratory Medicine, Yamanashi Medical University, Tamaho, Nakakoma, Yamanashi 409-3898, Japan
    Search for articles by this author
  • Kaneo Satoh
    Affiliations
    Department of Clinical and Laboratory Medicine, Yamanashi Medical University, Tamaho, Nakakoma, Yamanashi 409-3898, Japan
    Search for articles by this author
  • Yukio Ozaki
    Correspondence
    Corresponding author: Dr. Yukio Ozaki, Department of Clinical and Laboratory Medicine, Yamanashi Medical University, Shimokato 1110, Tamaho, Nakakoma, Yamanashi 409-3898, Japan. Tel: +81 (55) 273 6770; Fax: +81 (55) 273 6713
    Affiliations
    Department of Clinical and Laboratory Medicine, Yamanashi Medical University, Tamaho, Nakakoma, Yamanashi 409-3898, Japan
    Search for articles by this author

      Abstract

      Although communications between platelets and endothelial cells or other blood cells are important in in vivo thrombus formation, laboratory platelet function tests are usually performed in isolation from these surrounding cells. In this study, we evaluated the effect of an antiplatelet drug, ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine), on platelet aggregation in the presence and absence of human umbilical vein endothelial cells (HUVECs) and with the use of platelet-rich plasma (PRP) or whole blood as platelet samples. Stimulation-dependent platelet aggregation was weakened in the presence of HUVECs, which was especially prominent when the thrombin receptor-activating peptide SFLL (compared with ADP and epinephrine) was used as an aggregating agent. Ibudilast hardly affected SFLL-induced platelet aggregation (in PRP), while this antiplatelet agent was found to clearly inhibit this SFLL-induced response in a concentration-dependent manner, in the presence of HUVECs. Ibudilast tended to inhibit ADP- or epinephrine-induced platelet aggregation in the presence of HUVECs, but the effects were not statistically significant. Enhanced inhibition by ibudilast of SFLL-induced platelet aggregation (in the presence of HUVECs) was reproduced with the use of whole blood samples when a screen filtration pressure method was employed. It is suggested that the platelet aggregation studies in the presence of endothelial cells and/or other blood cells provide us with valuable information on platelet reactivity in vivo and improvement of antiplatelet therapy.

      Keywords

      Abbreviations:

      PGI2, prostacyclin (), NO, nitric oxide (), PRP, platelet-rich plasma (), HUVEC, human umbilical vein endothelial cell ()
      To read this article in full you will need to make a payment
      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Motwani JG
        • Topol EJ
        Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention.
        Circulation. 1998; 97: 916-931
        • Goldszmidt A
        • Wityk RJ
        Recent advances in stroke therapy.
        Curr Opin Neurol. 1998; 11: 57-64
        • Joseph JE
        • Machin SJ
        New antiplatelet drugs.
        Blood Rev. 1997; 11: 178-190
        • Theroux P
        Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin?.
        Am Heart J. 1997; 134: S62-S70
        • Miller DB
        Secondary prevention for ischemic heart disease. Relative numbers needed to treat with different therapies.
        Arch Intern Med. 1997; 157: 2045-2052
        • Marcus AJ
        Thrombosis and inflammation as multicellular processes: significance of cell–cell interactions.
        Semin Hematol. 1994; 31: 261-269
        • Zimmerman GA
        • McIntyre TM
        • Prescott SM
        Adhesion and signaling in vascular cell–cell interactions.
        J Clin Invest. 1996; 98: 1699-1702
        • Moncada S
        • Gryglewski R
        • Bunting S
        • Vane JR
        An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.
        Nature. 1976; 263: 663-665
        • Marcus AJ
        • Weksler BB
        • Jaffe EA
        • Broekman MJ
        Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells.
        J Clin Invest. 1980; 66: 979-986
        • Murata T
        • Ushikubi F
        • Matsuoka T
        • Hirata M
        • Yamasaki A
        • Sugimoto Y
        • Ichikawa A
        • Aze Y
        • Tanaka T
        • Yoshida N
        • Ueno A
        • Ohishi S
        • Narumiya S
        Altered pain perception and inflammatory response in mice lacking prostacyclin receptor.
        Nature. 1997; 388: 678-682
        • Andersen NH
        • Eggerman TL
        • Harker LA
        • Wilson CH
        • De B
        On the multiplicity of platelet prostaglandin receptors: I. Evaluation of competitive antagonism by aggregometry.
        Prostaglandins. 1980; 19: 711-735
        • Marcus AJ
        • Broekman MJ
        • Drosopoulos JH
        • Islam N
        • Alyonycheva TN
        • Safier LB
        • Hajjar KA
        • Posnett DN
        • Schoenborn MA
        • Schooley KA
        • Gayle RB
        • Maliszewski CR
        The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.
        J Clin Invest. 1997; 99: 1351-1360
        • Valles J
        • Santos MT
        • Aznar J
        • Marcus AJ
        • Martinez-Sales V
        • Portoles M
        • Broekman MJ
        • Safier LB
        Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment.
        Blood. 1991; 78: 154-162
        • Ohashi M
        • Ohkubo H
        • Kito J
        • Nishino K
        A new vasodilator 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine (KC-404) has a dual mechanism of action on platelet aggregation.
        Arch Int Pharmacodyn Ther. 1986; 283: 321-334
        • Hisayama T
        • Takayanagi I
        • Goromaru N
        • Okamoto Y
        Potentiating effect of 3-isobutyryl-2-isopropylpyrazolo-[1,5a]-pyridine (KC-404), a new cerebral vasodilator with anti-platelet activity, on prostacyclin-induced increase of cyclic AMP content in platelets of rat.
        Gen Pharmacol. 1989; 20: 183-186
        • Fukuyama H
        • Kimura J
        • Yamaguchi S
        • Yamauchi H
        • Ogawa M
        • Doi T
        • Yonekura Y
        • Konishi J
        Pharmacological effects of ibudilast on cerebral circulation: a pet study.
        Neurol Res. 1993; 15: 169-173
        • Miura Y
        • Yatomi Y
        • Rile G
        • Ohmori T
        • Satoh K
        • Ozaki Y
        Rho-mediated phosphorylation of focal adhesion kinase and myosin light chain in human endothelial cells stimulated with sphingosine 1-phosphate, a bioactive lysophospholipid released from activated platelets.
        J Biochem. 2000; 127: 909-914
        • Igawa T
        • Tani T
        • Chijiwa T
        • Shiragiku T
        • Shimidzu S
        • Kawamura K
        • Kato S
        • Unemi F
        • Kimura Y
        Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells.
        Thromb Res. 1990; 57: 617-623
        • Born GVR
        Aggregation of blood platelets by adenosine diphosphate and its reversal.
        Nature. 1962; 194: 927-929
        • Born GVR
        Observations on the change in shape of blood platelets brought about by adenosine diphosphate.
        J Physiol. 1970; 209: 487-511
        • Ozaki Y
        • Satoh K
        • Yatomi Y
        • Yamamoto T
        • Shirasawa Y
        • Kume S
        Detection of platelet aggregates with a particle counting method using light scattering.
        Anal Biochem. 1994; 218: 284-294
        • Dhall DP
        • Engeset J
        • McKenzie FN
        • Matheson NA
        Screen filtration pressure of blood — an evaluation.
        Cardiovasc Res. 1969; 3: 147-154
        • Dhall DP
        • Matheson NA
        Platelet aggregate filtration pressure — a method of measuring platelet aggregation in whole blood.
        Cardiovasc Res. 1969; 3: 155-160
        • Ozeki Y
        • Sudo T
        • Toga K
        • Nagamura Y
        • Ito H
        • Ogawa T
        • Kimura Y
        Characterization of whole blood aggregation by a new type aggregometer with screen filtration pressure method.
        Thromb Res. 2000; (in press)
        • Vu T-KH
        • Hung DT
        • Wheaton VI
        • Coughlin SR
        Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.
        Cell. 1991; 64: 1057-1068
        • Ngaiza JR
        • Jaffe EA
        A 14 amino acid peptide derived from the amino terminus of the cleaved thrombin receptor elevates intracellular calcium and stimulates prostacyclin production in human endothelial cells.
        Biochem Biophys Res Commun. 1991; 179: 1656-1661
        • Allen GT
        • Normandin D
        • Antonaccio MJ
        Involvement of the “tethered ligand” receptor in thrombin-induced endothelium-mediated relaxations.
        Am J Physiol. 1993; 265: H1744-H1749
        • Schaeffer P
        • Riera E
        • Dupuy E
        • Herbert JM
        Nonproteolytic activation of the thrombin receptor promotes human umbilical vein endothelial cell growth but not intracellular Ca2+, prostacyclin, or permeability.
        Biochem Pharmacol. 1997; 53: 487-491
        • Kishi Y
        • Ohta S
        • Kasuya N
        • Tatsumi M
        • Sawada M
        • Sakita S
        • Ashikaga T
        • Numano F
        Ibudilast modulates platelet–endothelium interaction mainly through cyclic GMP-dependent mechanism.
        J Cardiovasc Pharmacol. 2000; 36: 65-70